Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00400634 · ClinicalTrials.gov registry record · Phase 2
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
A Phase 2 study, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00400634 is a Phase 2 study that has completed, run by Sangamo Therapeutics. The registered enrollment target is 58 participants.
The verdict
NCT00400634, a Phase 2 study, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this double blind study is to determine whether CERE-120 (adeno-associated virus serotype 2 \[AAV2\]-neurturin \[NTN\]) is effective and safe in the treatment of patients with idiopathic Parkinson's Disease. CERE-120 is administered via bilateral stereotactic injections targeting the putaminal region of the brain. The design of this study involves approximately 34 patients receiving CERE-120 treatment via stereotactic surgery and approximately 17 patients receiving sham stereotactic surgery (no CERE-120 administered).
Interventions
- PROCEDURE Sham Surgery
- DRUG CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00400634
The ClinicalTrials.gov registry entry for NCT00400634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Surgery is the first listed.
NCT00400634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00400634 about?
NCT00400634 is a clinical study titled "Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease". The purpose of this double blind study is to determine whether CERE-120 (adeno-associated virus serotype 2 \[AAV2\]-neurturin \[NTN\]) is effective and safe in the treatment of patients with idiopathic Parkinson's Disease. CERE-120 is administered via bilateral stereotactic injections targeting the ...
What is the current status of trial NCT00400634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2006-11. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00400634?
The interventions under investigation include: Sham Surgery (PROCEDURE), CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) (DRUG).
Who is sponsoring clinical trial NCT00400634?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.